Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints

Farfour, Éric; Degand, Nicolas; Riverain, E.; Fihman, Vincent; Brun, Cécile; Ponfilly, Gauthier Péan de; Muggeo, Anaëlle; Jousset, Agnès B; Piau, Caroline; Lesprit, Philippe; Chatelain, N.; Dortet, Laurent; Poisson, Agathe; Guillard, T.; Limelette, Anne; Mizrahi, Assaf; Monnier, Alban Le; Fournier, Damien; Potron, Anaïs; Morand, P; Janvier, Frédéric; Otto, Marie-Pierre; Woerther, Paul‐Louis; Decousser, J.-W.; Corvec, Stéphane; Plouzeau-Jayle, Chloé; Broutin, Lauranne; Yin, Nicolas; Héry-Arnaud, Geneviève; Grillon, Antoine; Lecuru, Marion; Bille, Emmanuelle; Godreuil, Sylvain; Pierre, Hélène; Amara, Marlène; Henry, A. F. X.; Zahar, Jean‐Ralph; Carbonelle, Etienne; Jauréguy, Françoise; Lomont, Alexandra; Isnard, Christophe; Cattoir, Vincent; Canis, F.; Diedrich, Tristan; Flevin, Emilie; Mérens, Audrey; Jacquier, Hervé; Gyde, Esther

doi:10.1016/j.medmal.2020.07.003

Cited by 5 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, with updated breakpoints, the rate of resistance to fosfomycin was reported to increase of about 3-fold for all Enterobacterales species, reaching 80% in Klebsiella spp. [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France

et al. 2022

Self Cite

View full text Add to dashboard Cite

In the context of increasing antimicrobial resistance in Enterobacterales, the management of these UTIs has become challenging. We retrospectively assess the prevalence of antimicrobial resistance in Enterobacterales isolates recovered from urinary tract samples in France, between 1 September 2017, to 31 August 2018. Twenty-six French clinical laboratories provided the susceptibility of 134,162 Enterobacterales isolates to 17 antimicrobials. The most frequent species were E. coli (72.0%), Klebsiella pneumoniae (9.7%), Proteus mirabilis (5.8%), and Enterobacter cloacae complex (2.9%). The overall rate of ESBL-producing Enterobacterales was 6.7%, and ranged from 1.0% in P. mirabilis to 19.5% in K. pneumoniae, and from 3.1% in outpatients to 13.6% in long-term care facilities. Overall, 4.1%, 9.3% and 10.5% of the isolates were resistant to cefoxitin, temocillin and pivmecillinam. Cotrimoxazole was the less active compound with 23.4% resistance. Conversely, 4.4%, 12.9%, and 14.3% of the strains were resistant to fosfomycin, nitrofurantoin, and ciprofloxacin. However, less than 1% of E. coli was resistant to fosfomycin and nitrofurantoin. We identified several trends in antibiotics resistances among Enterobacterales isolates recovered from the urinary tract samples in France. Carbapenem-sparing drugs, such as temocillin, mecillinam, fosfomycin, cefoxitin, and nitrofurantoin, remained highly active, including towards ESBL-E.

show abstract

“…Indeed, with updated breakpoints, the rate of resistance to fosfomycin was reported to increase of about 3-fold for all Enterobacterales species, reaching 80% in Klebsiella spp. [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fosfomycin was effective therapy for UTIs caused by ESBL-producing E. coli 190 . Resistance to fosfomycin is rare 191,192 , but fosfomycin-resistance genes (fosA3) have been documented among ESBL-producing E. coli and K. pneumoniae isolates; all coharbored bla CTX-M resistance genes 193 . Clinical and microbiological resistance to fosfomycin among…”

Section: Fosfomycin (Antibiotic With a Novel Mechanism Of Action)mentioning

confidence: 99%

Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases

Lynch¹,

Clark

Zhanel

2021

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

aminoglycosides (AG); antimicrobial resistance (AMR); -lactamase inhibitors (BLI); blood stream infections (BSIs) ; carbapenem (CP); carbapenemase (CPase); carbapenem-resistant (CR); carbapenemresistant Enterobacterales (CRE) ;-lactam inhibitor (BLI); CP-resistant K. pneumoniae (CRKP); CPsusceptible K. pneumoniae (CSKP); ceftazidime/avibactam (CAZ-AVI); cephalosporins (CEPHS); central line-associated (CLA); central venous catheter (CVC); community-acquired infection (CAI); complicated intra-abdominal infection (c-IAI); complicated urinary tract infection (c-UTI); defined daily dose (DDD) ; extended-spectrum -lactamases (ESBLs); extensively Drug Resistant (eXDR); fluoroquinolones (FQ); Gram negative bacteria (GNB); gross domestic product per capita (GDPPC); high-income countries (HICs); hospital acquired infection (HAI); imipenem-relebactam (IMI-REL); intensive care units (ICUs); Klebsiella pneumoniae carbapenemases (KPCs); long-term care facilities (LTCFs); low-and middleincome countries (LMICs); mechanical ventilation; metallo-lactamase (MBL); minimal inhibitory concentration (MIC); mobile genetic elements (MGEs); multidrug resistant (MDR); New Delhi Metalloproteinase-1 (NDM-1); non-Proteus Enterobacterales (NPE); organ transplant recipients (OTR); piperacillin/tazobactam (PTZ); solid organ transplant (SOT); tigecycline (TGC); ventilator-associated pneumonia (VAP)

show abstract

“…We do not believe that the overall high rates of PIV resistance in our study can be explained by increasing selection pressure due to higher consumption rates. In Germany, the number of PIV prescriptions has indeed increased steadily in both the hospital (0.01 defined daily doses (DDD)/100 patient days in 2017 to 0.48 DDD/100 patient days in 2021 [24]) and outpatient sectors (116 DDD/1,000 patient days in 2017 to 2,228 DDD/1,000 patient days in 2020 [31]). However, we saw a consistent decline in PIV resistance rates in E. coli from 2019 (19% resistant isolates) to 2021 (14.9% resistant isolates).…”

Section: Table 3cmentioning

confidence: 99%

Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021

Stoltidis-Claus,

Rosenberger,

Mandraka

et al. 2023

Eurosurveillance

View full text Add to dashboard Cite

Introduction Empirical therapy for the treatment of urinary tract infections should be tailored to the current distribution and susceptibility of potential pathogens to ensure optimal treatment. Aim We aimed to provide an up-to-date overview of the epidemiology and susceptibility of Enterobacterales isolated from urine in Germany. Methods We retrospectively analysed antimicrobial susceptibility data from 201,152 urine specimens collected between January 2016 and June 2021 from in- and outpatients. Multiple logistic regression analysis was used to evaluate the association between year of investigation and antibiotic resistance, adjusted for age, sex and species subgroup. Subgroup analyses were performed for midstream urine samples obtained from (i) female outpatients aged 15 to 50 years, (ii) female outpatients older than 50 years and (iii) male outpatients. Results Resistance rates of less than 20% were observed for nitroxoline (3.9%), fosfomycin (4.6%), nitrofurantoin (11.7%), cefuroxime (13.5%) and ciprofloxacin (14.2%). Resistance to trimethoprim/sulfamethoxazole (SXT) (20.1%), amoxicillin-clavulanic acid (20.5%), trimethoprim (24.2%), pivmecillinam (29.9%) and ampicillin (53.7%) was considerably higher. In the subgroup of outpatient women aged 15–50 years, resistance rates were generally lower. Resistance rates of all antibiotics decreased from 2016 to 2021. Multiple logistic regression revealed the lowest adjusted odds ratio (ORadj) of 0.838 (95% confidence interval (CI): 0.819–0.858; p < 0.001) for pivmecillinam and the highest ORadj of 0.989 (95% CI: 0.972–1.007; p = 0.226) for nitrofurantoin. Conclusions Resistance has generally decreased over the past years, independent of sex, age and causative pathogen. Our data provide an important basis for empirical antibiotic recommendations in various settings and patient collectives.

show abstract

Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints

Cited by 5 publications

References 14 publications

Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France

Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France

Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases

Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021

Contact Info

Product

Resources

About